Protein factors of oxidative stress and atherogenesis in patients with arterial hypertension

L. S. Mkhitaryan, O. B. Kuchmenko, O. G. Kupchynska, I. N. Ievstratova

Abstract


The aim of this study was to evaluate the protein components of HDL in patients with arterial hypertension (AH). The study included 30 patients (mean age of 47.4±3.3 years) with AH 2 grade. The accumulation of carbonyl oxidation protein products in blood, HDL and LDL eventually results in oxidative modification of HDL and LDL, and loss of its functional properties. The activity of HDL-associated enzymes (PON1 and MPO) is the most informative indicator of functional state of HDL, and not the level of HDL-Cholesterol. Changes of MPO and PON1 activity may serve as a useful marker of dysfunctional HDL. Our evaluation showed a significant decrease of PON1 activity and increase of MPO activity that may contribute to the HDL oxidation, irrespective of HDL-Cholesterol levels. Demonstrated changes in the functional state of HDL, in our opinion, create a predisposition to development and progression of atherosclerosis in patients with AH.


Keywords


arterial hypertension; atherogenesis; oxidative stress; paraoxonase-1; myeloperoxidase

Full Text:

PDF

References


Dinh Q.N., Drummond G.R., Sobey C.G., Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension // Biomed. Res. Int. – 2014;2014:406960. doi: 10.1155/2014/406960.

Dubinina Е.Е. Oxidative modification of serum proteins. A method of determination it / Е.Е. Dubinina, S.O. Burmistrov, D.A. Khodov, I.G. Porotov // VVopr. Med. Khim. - 1995. - Vol. 41, No. 1. – P. 24 - 26.

Eren E. Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis / E. Eren, N. Yilmaz, O. Aydin // Cholesterol. – 2013. – Article ID 792090, 10 p.

Fu X. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase / X. Fu, S.Y. Kassim, W.C. Parks, J.W. Heinecke // J. Biol. Chem. – 2001. – Vol. 276, No. 44. – P. 41279 - 41287.

Gorudko I.V. Increased myeloperoxidase activity is a risk factor for ischemic heart disease in patients with diabetes mellitus / I.V. Gorudko, V.A. Kostevich, A.V. Sokolov, I.V. Buko, E.E. Konstantinova, N.L. Tsapaeva, E.V. Mironova, E.T. Zakharova, V.B. Vasilyev, S.N. Cherenkevich, O.M. Panasenko // Biomed. Khim. – 2012. – Vol. 58, No. 4. – P. 475 – 484.

Huang Y. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex / Y. Huang, Zh. Wu, M. Riwanto, S. Gao, B.S. Levison, X. Gu, X. Fu, M.A. Wagner, C. Besler, G. Gerstenecker, R. Zhang, X.M. Li, A.J. DiDonato, V. Gogonea, W.H. Tang, J.D. Smith, E.F. Plow, P.L. Fox, D.M. Shih, A.J. Lusis, E.A. Fisher, J.A. DiDonato, U. Landmesser, S.L. Hasen // J. Clin. Invest. – 2013. – Vol. 123, No.9. – P. 3815 – 3828.

Ievstratova I.N., Mkhitaryan L.S. «A method of diagnosis of progressive atherosclerosis», Patent of Ukraine №30972 А, №2, 2000.

Koroluk M.A. A method of determination of catalase activity / M.A. Koroluk, M.I. Ivanova // Laboratornoe delo. – 1988. – No. 1. - P. 16 - 18.

Kovalenko V.M. Molecular and genetic peculiarities of the paraoxonase functioning and importance in the development of cardiovascular pathology / V.M. Kovalenko, O.B. Kuchmenko, L.S. Mkhitaryan // The Ukrainian Journal of Cardiology. – 2014. - №5. – P. 105 – 116.

Kubala L. The potentiation of myeloperoxidase activity by the glycosaminoglycan-dependent binding of myeloperoxidase to proteins of the extracellular matrix / L. Kubala, H. Kolářová, J. Víteček, S. Kremserova, A. Klinke, D. Lau, A.L. Chapman, S.A. Baldus, J.P. Eiserich // Biochim. Biophys. Acta. – 2013. – Vol. 1830, No. 10. – P. 4524 – 4536.

Libby P. Fanning the flames: inflammation in cardiovascular diseases // Cardiovascular Research. – 2015. – Vol. 107. – P. 307 – 309.

Loria V. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes / V. Loria, I. Dato, F. Graziani, L.M. Biasucci // Mediators Inflamm. – 2008. – P. 135625.

Mangge H. Beyond cholesterol – new cardiovascular biomarkers // Nestle Nutr. Inst. Workshop Ser. – 2016. – Vol. 84. – P. 81 – 88.

Manolescu B.N. Effect of the nutritional supplement ALAnerv® on the serum PON1 activity in post-acute stroke patients / B.N. Manolescu, M. Berteanu, D. Cinteza // Pharmacological Reports. – 2013. – Vol. 65. – P. 743 – 750.

Misra H.P. Role of Superoxide anion in the autooxidation of epinephrine. A simple assay for superoxide dismutase / H.P. Misra, I. Fridovich // J.Biol.Chem. - 1972. - Vol. 247, № 10. -P. 3170 - 3175.

Razavi A.E. Association between HDL particles size and myeloperoxidase/paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary syndrome / A.E. Razavi, G. Basati, J. Varshosaz, S. Abdi // Acta Medica Iranica. – 2013. – Vol. 51, No. 6. – P. 365 – 371.

Sinha N. Oxidative stress and antioxidant in hypertension – a current review / N. Sinha P.K. Dadla // Curr. Hypertens. Rev. – 2015. – Vol.11, No. 2. – P. 132 – 142.

Solak Y. Hypertension as an autoimmune and inflammatory disease / Y. Solak, B. Afsar, N.D. Vaziri, G. Aslan, C.E. Yalcin, A. Covic, M. Kanbay // Hypertens. Res. – 2016. – Apr. 7. doi: 10.10380/hr.2016.35.

Stalnaya I.D. A method of MDA determination with help of TBA / I.D. Stalnaya, T.G. Garischvili // Modern methods in biochemistry. - Moscow: Medicina, 1977. - P. 66 - 68.


GOST Style Citations






DOI: https://doi.org/10.24959/89408

Abbreviated key title: Ukr. bìofarm. ž.

ISSN 2519-8750 (Online), ISSN 2311-715X (Print)